康诺亚(02162.HK) 公布，旗下司普奇拜单抗注射液“康悦达”于周三(25日)在首都医科大学附属北京同仁医院开出全国首张处方。康悦达为国内首个、全球唯二获批上市的IL-4Rα抗体药物，于本月中获国家药品监督管理局批准上市，用于治疗慢性鼻窦炎伴鼻息肉适应症。另外，该药用于治疗季节性过敏性鼻炎的药品上市许可申请亦已获受理。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-24 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.